+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032- Product Image
Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032- Product Image
Sale

Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011425
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Breast Cancer Liquid Biopsy Market is projected to reach USD 1.64 Billion in 2026. It is expected to continue growing at a CAGR of 8.23%, reaching USD 2.65 Billion by 2032.

Breast cancer liquid biopsy is moving from a complementary research tool to a clinically relevant precision oncology approach for metastatic disease management, therapy selection, resistance monitoring, and minimal residual disease research. The field centers on blood-based biomarkers such as circulating tumor DNA, circulating tumor cells, extracellular vesicles, methylation signatures, and fragmentomics, with next-generation sequencing and digital PCR enabling noninvasive genomic profiling when tissue is limited or repeat biopsy is impractical.

The clinical need is substantial. IARC GLOBOCAN 2022 estimated about 2.3 million new breast cancer cases and approximately 670,000 deaths worldwide, making breast cancer one of the most commonly diagnosed cancers globally. Liquid biopsy adoption is being strengthened by guideline-aligned use of plasma testing in advanced breast cancer, FDA-cleared and FDA-approved companion diagnostic pathways, and expanding demand for biomarkers such as ESR1, PIK3CA, BRCA1/2, HER2-related alterations, and tumor mutational features.

Transformative Shifts in the Breast Cancer Liquid Biopsy Landscape

The breast cancer liquid biopsy landscape is being reshaped by a shift from single-gene testing toward comprehensive, multi-analyte molecular profiling. In metastatic hormone receptor-positive breast cancer, ESR1 mutation detection has become especially important because acquired ESR1 alterations can emerge after aromatase inhibitor exposure and guide endocrine therapy decisions. PIK3CA mutation assessment also remains central for identifying patients who may benefit from PI3K pathway-targeted therapy.

Another major shift is the movement of liquid biopsy into longitudinal care. Rather than relying only on a baseline tissue specimen, oncologists increasingly use plasma-based testing to track clonal evolution, detect resistance mechanisms, and evaluate disease dynamics over time. Regulatory scrutiny, payer evidence requirements, and the European Union In Vitro Diagnostic Regulation are also raising expectations for analytical validity, clinical validity, quality systems, and transparent performance claims.

Cumulative Impact of Artificial Intelligence on Liquid Biopsy

Artificial intelligence is accelerating breast cancer liquid biopsy by improving signal extraction from low-abundance circulating tumor DNA, integrating genomic and clinical variables, and supporting quality control across sequencing workflows. AI-enabled bioinformatics can help distinguish tumor-derived variants from sequencing artifacts or clonal hematopoiesis, a critical requirement because false positives can affect treatment selection and patient confidence.

The most valuable use cases are emerging in multimodal interpretation, where machine learning combines variant allele frequency, copy-number change, methylation, fragment size, clinical history, imaging, and treatment response. However, responsible adoption requires externally validated models, representative datasets, explainability, cybersecurity controls, and compliance with HIPAA, GDPR, IVDR, FDA software guidance, and local laboratory accreditation standards.

Key Regional Insights: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

North America remains a key commercialization hub for breast cancer liquid biopsy because the United States has mature CLIA and CAP laboratory infrastructure, FDA-recognized companion diagnostic pathways, broad oncology trial activity, and increasing use of plasma-based comprehensive genomic profiling in advanced cancer. Canada benefits from strong provincial cancer programs, although reimbursement and access can vary by province. Europe is shaped by national health technology assessment systems, GDPR requirements, and IVDR implementation, with Germany, France, Italy, Spain, and the United Kingdom advancing molecular oncology adoption through cancer networks and public health systems.

Asia-Pacific shows rising demand driven by large breast cancer populations, expanding oncology infrastructure, and increased NGS adoption in China, Japan, South Korea, Australia, India, and ASEAN markets. Latin America, including Brazil and Mexico, is improving access through private-sector diagnostics and reference laboratory partnerships, but affordability and uneven reimbursement remain constraints. The Middle East, led by GCC health system modernization, is investing in precision oncology, while Africa has a significant opportunity for noninvasive diagnostics but faces barriers related to laboratory capacity, late-stage diagnosis, workforce shortages, and sustainable funding.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Within ASEAN, breast cancer liquid biopsy adoption is supported by growing private hospital networks, regional reference laboratories, and medical tourism hubs in Singapore, Thailand, and Malaysia, while Indonesia, Vietnam, and the Philippines represent access-expansion opportunities as oncology capacity improves. GCC countries are prioritizing precision medicine through national health strategies, advanced tertiary care centers, and investment in genomic medicine, making liquid biopsy relevant for oncology modernization, specialist care pathways, and reduced reliance on repeated invasive tissue biopsy.

The European Union is defined by IVDR compliance, cross-border evidence expectations, GDPR-governed health data use, and demand for clinically validated diagnostics that can withstand payer review. BRICS countries combine large patient populations with fast-evolving local diagnostics industries, particularly in China and India, while Brazil and South Africa face the challenge of scaling access across mixed public-private systems. G7 markets generally lead in regulatory maturity, reimbursement evaluation, oncology innovation, and guideline-driven biomarker testing, while NATO countries overlap strongly with advanced European and North American health systems where validated, secure, and interoperable liquid biopsy solutions are favored.

Key Country Insights Across Major Breast Cancer Liquid Biopsy Markets

The United States is central to breast cancer liquid biopsy commercialization due to FDA-approved companion diagnostic precedents, extensive clinical trial networks, established molecular pathology workflows, and strong demand for plasma-based testing in metastatic oncology. Canada offers strong cancer registries and academic oncology systems, while Mexico and Brazil are expanding molecular testing through private laboratories, oncology centers, and reference testing models. In Europe, the United Kingdom is advancing genomic medicine through NHS-linked initiatives, Germany has strong molecular pathology capacity, France supports structured cancer innovation programs, and Italy and Spain are scaling precision oncology through regional networks; Russia has scientific capabilities, although access, reimbursement, and import constraints can affect adoption.

China is a major growth engine with large patient volume, domestic sequencing capacity, and NMPA oversight, while India combines rising breast cancer incidence with affordability-driven demand for scalable testing and broader oncology access. Japan has an established PMDA reimbursement framework for oncology diagnostics, South Korea has advanced digital health and sequencing capabilities, and Australia benefits from strong clinical research networks and centralized cancer care. Across these countries, market success depends on local evidence generation, reimbursement alignment, oncologist education, sample logistics, data protection compliance, and validated performance in diverse populations.

Actionable Recommendations for Breast Cancer Liquid Biopsy Leaders

Industry leaders should prioritize clinically actionable use cases first, especially metastatic breast cancer therapy selection, ESR1 and PIK3CA resistance profiling, and monitoring where evidence supports decision-making. Developers should design assays with clear intended use, transparent limits of detection, orthogonal validation, clonal hematopoiesis filtering, and performance data across low tumor-fraction samples. Partnerships with oncology networks, academic cancer centers, and biopharma sponsors can accelerate evidence generation and adoption.

Commercial strategy should align regulatory, reimbursement, and clinical education plans from the start. Organizations should invest in health economic evidence, real-world clinical utility studies, rapid turnaround logistics, secure data infrastructure, and AI governance. Regional market entry should be staged, beginning with high-readiness systems and expanding through reference laboratory collaborations, local regulatory submissions, and payer-facing value dossiers that demonstrate reduced invasive biopsy burden and improved precision therapy matching.

Research Methodology

This executive summary is developed using a structured secondary research approach anchored in publicly available, verifiable sources, including global cancer statistics from IARC and WHO, regulatory information from the FDA, EMA, PMDA, NMPA, and comparable national agencies, clinical guidance from oncology organizations, peer-reviewed literature, reimbursement policies, health system documentation, and public clinical trial registries. Emphasis is placed on data that can be independently corroborated and is relevant to breast cancer liquid biopsy commercialization.

The methodology evaluates market dynamics through clinical utility, technology readiness, regulatory maturity, reimbursement pathways, regional oncology infrastructure, and biomarker relevance. Insights are triangulated across scientific evidence, policy developments, diagnostic adoption patterns, and country-level healthcare capacity. Claims are intentionally framed to avoid unsupported market sizing and to reflect the current evidence base for liquid biopsy in breast cancer.

Conclusion

Breast cancer liquid biopsy is becoming an important precision oncology tool as clinicians seek faster, less invasive, and more repeatable ways to understand tumor biology. The strongest near-term opportunities are in advanced and metastatic breast cancer, where plasma-based genomic profiling can help identify actionable mutations, monitor resistance, and support therapy selection when tissue is unavailable or insufficient.

Sustainable adoption will depend on rigorous validation, reimbursement evidence, regulatory compliance, responsible AI integration, and equitable access. Organizations that combine scientific credibility, clinical workflow fit, secure data practices, and country-specific commercialization plans will be best positioned to create long-term value in breast cancer liquid biopsy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Breast Cancer Liquid Biopsy Market, by Offering
7.1. Introduction
7.2. Instruments
7.2.1. Microfluidic Platforms
7.2.2. Analyzers
7.3. Consumables
7.3.1. Reagents & Kits
7.3.2. Assay Cartridges
7.4. Software & Informatics
7.4.1. Bioinformatics Analysis
7.4.2. Variant Calling
7.5. Services
7.5.1. Testing
7.5.2. Processing & Profiling
8. Breast Cancer Liquid Biopsy Market, by Biomarker Type
8.1. Introduction
8.2. Circulating Free DNA
8.3. Circulating Tumor Cells
8.4. Circulating Tumor DNA
8.5. Exosomes
8.5.1. Exosomal Protein
8.5.2. Exosomal RNA
9. Breast Cancer Liquid Biopsy Market, by Technology
9.1. Introduction
9.2. BEAMing
9.3. Polymerase Chain Reaction (PCR)
9.4. Next Generation Sequencing
10. Breast Cancer Liquid Biopsy Market, by Sample Type
10.1. Introduction
10.2. Plasma
10.3. Saliva
10.4. Serum
10.5. Urine
11. Breast Cancer Liquid Biopsy Market, by Cancer Stage
11.1. Introduction
11.2. Advanced Stage
11.3. Early Stage
12. Breast Cancer Liquid Biopsy Market, by Application
12.1. Introduction
12.2. Early Detection
12.2.1. High Risk Screening
12.2.2. Population Screening
12.3. Minimal Residual Disease
12.4. Recurrence Monitoring
12.5. Treatment Selection
13. Breast Cancer Liquid Biopsy Market, by End User
13.1. Introduction
13.2. Diagnostic Laboratories
13.3. Hospitals
13.4. Research Institutes
14. Breast Cancer Liquid Biopsy Market, by Region
14.1. North America
14.2. Europe
14.3. Asia-Pacific
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Breast Cancer Liquid Biopsy Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Breast Cancer Liquid Biopsy Market, by Country
16.1. United States
16.2. China
16.3. Canada
16.4. Germany
16.5. Brazil
16.6. Mexico
16.7. Japan
16.8. India
16.9. United Kingdom
16.10. France
16.11. Italy
16.12. Australia
16.13. South Korea
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Adaptive Biotechnologies Corporation
18.2. Agilent Technologies, Inc.
18.3. Becton, Dickinson and Company
18.4. Bio-Rad Laboratories, Inc.
18.5. Biodesix, Inc.
18.6. BioVIew Ltd.
18.7. Eurofins Scientific SE
18.8. Exact Sciences Corporation
18.9. F. Hoffmann-La Roche AG
18.10. Fluxion Biosciences Inc.
18.11. Grail, LLC
18.12. Guardant Health, Inc.
18.13. Illumina, Inc.
18.14. Isogen Life Science B.V.
18.15. Johnson & Johnson Services, Inc.
18.16. Laboratory Corporation of America Holdings
18.17. Menarini Group
18.18. Merck KGaA
18.19. Myriad Genetics, Inc.
18.20. Natera Inc.
18.21. Neogenomics Laboratories, Inc.
18.22. OncoDNA SA
18.23. Qiagen N.V.
18.24. Sysmex Corporation
18.25. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL MICROFLUIDIC PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL MICROFLUIDIC PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL MICROFLUIDIC PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ASSAY CARTRIDGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ASSAY CARTRIDGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ASSAY CARTRIDGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BIOINFORMATICS ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL BIOINFORMATICS ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BIOINFORMATICS ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL VARIANT CALLING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL VARIANT CALLING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL VARIANT CALLING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PROCESSING & PROFILING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PROCESSING & PROFILING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PROCESSING & PROFILING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CIRCULATING FREE DNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CIRCULATING FREE DNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CIRCULATING FREE DNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL EXOSOMES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL EXOSOMES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL EXOSOMES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL EXOSOMAL PROTEIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL EXOSOMAL PROTEIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL EXOSOMAL PROTEIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL EXOSOMAL RNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL EXOSOMAL RNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL EXOSOMAL RNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BEAMING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BEAMING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BEAMING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PLASMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SERUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SERUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ADVANCED STAGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ADVANCED STAGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ADVANCED STAGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL EARLY STAGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL EARLY STAGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL EARLY STAGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL EARLY DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL EARLY DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL EARLY DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HIGH RISK SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HIGH RISK SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HIGH RISK SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL POPULATION SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL POPULATION SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL POPULATION SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL TREATMENT SELECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL TREATMENT SELECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL TREATMENT SELECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 135. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 136. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 137. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 138. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 139. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 140. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 141. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 142. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 143. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 144. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 145. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 146. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 176. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 177. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 178. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 179. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 180. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 181. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 182. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 183. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 184. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 185. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 186. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 188. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 206. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 207. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 208. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 209. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 210. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 211. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 212. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 213. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 214. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 215. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 216. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 217. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 219. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 220. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 221. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 222. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 223. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 224. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 225. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 226. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 227. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 228. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 229. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 230. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 231. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 247. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 248. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 249. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 250. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 251. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 252. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 253. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 254. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 255. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 256. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 257. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 258. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 259. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 261. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 262. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 263. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 264. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 265. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 266. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 267. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 268. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 269. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 270. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 271. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 272. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 273. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 275. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 276. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 277. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 278. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 279. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 280. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 281. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 282. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 283. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 284. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 285. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 286. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 287. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 305. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 306. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 307. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 308. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 309. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 310. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 311. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 312. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 313. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 314. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 316. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 319. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 320. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 321. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 322. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 323. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 324. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 325. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 326. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 327. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 328. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 329. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 330. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 331. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 332. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 333. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 334. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CONSUMABLES, 2017-2032 (USD MILLION)
TABLE 335. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SOFTWARE & INFORMATICS, 2017-2032 (USD MILLION)
TABLE 336. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2017-2032 (USD MILLION)
TABLE 337. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 338. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2017-2032 (USD MILLION)
TABLE 339. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 340. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 341. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2017-2032 (USD MILLION)
TABLE 342. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 343. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2017-2032 (USD MILLION)
TABLE 344. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 345. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 346. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 347. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLI

Companies Mentioned

  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biodesix, Inc.
  • BioVIew Ltd.
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Fluxion Biosciences Inc.
  • Grail, LLC
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Isogen Life Science B.V.
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Menarini Group
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera Inc.
  • Neogenomics Laboratories, Inc.
  • OncoDNA SA
  • Qiagen N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.64 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.65 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Breast Cancer Liquid Biopsy - Global Strategic Business Report - Product Image

Breast Cancer Liquid Biopsy - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
Liquid Biopsy Market - Global Forecast 2026-2032 - Product Image

Liquid Biopsy Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
?Breast Cancer Liquid Biopsy Market Report by Product Service, Circulating Biomaker, End User, and Region 2026-2034 - Product Image

?Breast Cancer Liquid Biopsy Market Report by Product Service, Circulating Biomaker, End User, and Region 2026-2034

  • Report
  • 147 Pages
  • Global
From
Breast Cancer Liquid Biopsy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Breast Cancer Liquid Biopsy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 135 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.